Biography
Tom Hawes serves on the Board of Directors of AbleTo, Octave Bio, Oncology Analytics, Patientco, Upward Health, and Verata as well as board observer for HeartFlow, Healthify, Phreesia, and Thrive Science. He was formerly on the Board of InVivoLink, Nexidia, and Wellspring Healthcare. Before joining Sandbox, Tom matched at Yale School of Medicine for residency and completed his first year of medical training at Greenwich Hospital. During his medical training, he worked on clinical studies at the ISK Institute for Orthopaedics and Sports Medicine and on outcomes research at the National Cancer Institute and NYMC’s Cardiothoracic Surgery Department. Tom holds a BA from Brigham Young University, an M.D. from New York Medical College and an MBA from Harvard Business School. He is also a Kauffman Fellow.

Biography
Dave brings to Thrive more than 25 years of diagnostics expertise in significant executive leadership roles in both startup and large-scale organizations. He currently serves as the Chief Executive Officer and Board Member for Thrive Earlier Detection. Prior to Thrive, he served as senior vice president and general manager of commercial operation for the Americas region at Illumina. There, Dave was responsible for all regional commercial functions, including sales, sales support, marketing, field service, technical support and field applications. Prior to joining Illumina, Dave was the chief commercial officer of Foundation Medicine, a company dedicated to transforming cancer care by identifying molecular alterations in each patient’s unique cancer and matching them with potential targeted therapies and immunotherapies. There, he led all commercial functions globally, including sales, marketing, client services, payer relations and medical affairs. Before that, Dave lead the oncology business unit at Life Technologies, responsible for the establishment of a clinical oncology strategy, centered on a central lab services model providing support to both research and clinical customers. After Thermo Fisher acquired Life Technologies, he transitioned to Thermo’s anatomic pathology division, where he oversaw all commercial operations globally.

Biography
Bill has more than 25 years of start-up experience in a broad range of medical specialties intersecting science, technology, clinical medicine, and business strategy. Prior to founding Octave Bioscience, he served as the CEO of Crescendo Bioscience which created novel measurement tools and software in the field of rheumatology. Prior to this, he was the President of Alpha BioPartners, a strategic consulting firm advising the launch of new life sciences companies. While at Alpha BioPartners, Bill created the business plan for Crescendo and co-founded Altheus Therapeutics and Biolytx Pharmaceuticals. Prior to that, he served as the initial CEO of Selexys Pharmaceuticals and interim CEO of Inoveon in ophthalmology. In the 1990s, Bill was Chairman and CEO of UroCor, a urology specialty diagnostics company which he scaled from start-up through IPO. Earlier in his career, he was Vice President of Baxter International’s $1.0 billion Scientific Products Division and held management positions at the American Hospital Supply and Becton Dickinson. He currently serves on the board of directors for CareDx, Navican, Genalyte and CoFactor. Previously he was on the board of Prometheus Laboratories. Bill holds a BS in Business Management from Bob Jones University.

Biography
Kevin Hrusovsky has dedicated his 30-year career to leading disruptive medical technology companies and shepherding a global movement to transform healthcare to Precision Health. He created Powering Precision Health foundation, an internationally renowned non-profit promoting a new era of medicine using biomarker innovation to achieve precision medicine. Kevin has always been committed to accelerating adoption and value creation for many “game changing” non-invasive early detection technologies for Oncology, Neurodegeneration and Cardiology which are transforming drug development and disease prevention. Before Quanterix, he was CEO of Caliper Life Sciences, and Zymark Corporation, as well as, President of Life Sciences at PerkinElmer. He is the recipient of several distinguished awards including the 2019 EY Entrepreneur of the Year®, the 2018 Lifetime Achievement Award for Leadership and the E.G. Bailey Entrepreneurship Award (2013), both from The Ohio State University.